C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526334-67-00

Enrollment

Registered

2026-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic weight management and other weight-related co-morbidities

Brief summary

AUCinf (if data permit, otherwise AUClast) and Cmax of PF-08653945.

Detailed description

Assessment of TEAEs: • Clinical safety laboratory tests, vital signs, 12-lead ECGs, C-SSRS, and PHQ-8.

Interventions

DRUGPF-08653945

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
AUCinf (if data permit, otherwise AUClast) and Cmax of PF-08653945.	—

Secondary

Measure	Time frame
Assessment of TEAEs: • Clinical safety laboratory tests, vital signs, 12-lead ECGs, C-SSRS, and PHQ-8.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 2, 2026